Results 21 to 30 of about 2,303 (187)

Effectiveness of Nirsevimab Immunoprophylaxis Administered at Birth to Prevent Infant Hospitalisation for Respiratory Syncytial Virus Infection: A Population-Based Cohort Study

Vaccines
Respiratory syncytial virus (RSV) infection is a frequent cause of hospitalisation in the first few months of life; however, this risk rapidly decreases with age.
Camino Trobajo-Sanmartín, Manuel Garcia Cenoz, Juan Carlos Muruzábal Torquemada   +2 more
exaly   +3 more sources

A phase I, randomized, placebo‐controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults

Clinical and Translational Science
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection (LRTI) in infants worldwide. Nirsevimab, an extended half‐life monoclonal antibody against RSV, is approved in China for the prevention of RSV lower respiratory ...
Xiaomeng Mao, Xiaohan Hua, Chengyi Wu, Xiaoyun Ge, Jie Zhang, Xiaojie Wu, Robert J. Kubiak, Ulrika Wählby Hamrén, Tonya Villafana, Georgios Christou, Jannine Green, Therese Takas, Yuwen Jin   +12 more
doaj   +2 more sources

The efficacy and safety of nirsevimab for the prevention of RSV infection among infants: A systematic review and meta-analysis

Frontiers in Pediatrics, 2023
BackgroundRespiratory syncytial virus (RSV) is a leading cause of morbidity and mortality among infants with a global incidence of 9.5% and a mortality rate of 2.2%. The management of RSV infection is mainly supportive and, aside from emerging monoclonal
Christian Wilson Turalde
exaly   +3 more sources

A single-center observational study of nirsevimab for prevention of RSV infection in preterm infants [PDF]

Frontiers in Pediatrics
ObjectiveThis study aims to evaluate the clinical efficacy of nirsevimab in preventing respiratory syncytial virus (RSV) infection in preterm infants, highlighting its potential to improve neonatal respiratory health.MethodsWe conducted a retrospective ...
Rina Su, Rigonggaowa A, Fang Yao, Yanbin An, Cheng Cai, Lei Yun   +5 more
doaj   +2 more sources

Coverage, Timing, Safety, and Determinants of Neonatal Intensive Care Unit Admission in Newborns Receiving Nirsevimab Prophylaxis for Respiratory Syncytial Virus [PDF]

Pathogens
Background: Nirsevimab, a long-acting monoclonal antibody targeting respiratory syncytial virus (RSV), has recently been introduced as universal prophylaxis in newborns and infants. Although clinical trials have shown high efficacy and a favorable safety
Maria Costantino, Valentina Giudice, Anna Maria Della Corte, Silvia Pecoraro, Anna Rita Frascogna, Giuseppe Marchesano, Sabino Moschella, Carmela Alfano, Federica Santaniello, Carmine Brengola, Giuseppina Napoletano, Virginia Caputo, Antonio Luciano, Assunta Santullo, Luca Pierri, Federica Aiello, Maria Carmen De Caro, Luciana Catena, Concetta Sarnataro, Francesco De Caro, Maria Grazia Corbo   +20 more
doaj   +2 more sources

Nirsevimab Treatment of RSV Bronchiolitis in Pediatric Emergency Departments

JAMA Network Open
Importance New resistant mutations of respiratory syncytial virus type B (RSV-B) have been observed during the first year of implementation nirsevimab treatment. During the second season of implementation of nirsevimab treatment in France, RSV-B was predominant.
Lenglart, Lea, Levy, Corinne, Basmaci, Romain, Levieux, Karine, Kramer, Rolf, de Mari, Pauline, Béchet, Stéphane, Launay, Elise, Perceval, Lise, Cohen, Laure, Aupiais, Camille, de Pontual, Loic, Rybak, Alexis, Ouldali, Naim, Cohen, Robert   +14 more
openaire   +4 more sources

Real-world impact of nirsevimab on RSV hospitalizations in children under 2 years of age: retrospective monocentric study in a large German tertiary pedatric center [PDF]

Molecular and Cellular Pediatrics
Background Respiratory syncytial virus (RSV) infection is a leading cause of hospitalization among infants and young children. Broad immunization with the monoclonal antibody nirsevimab represents a promising preventive strategy. However, real-world data
Moritz Bauer, Anke Wendt, Marcus A. Mall, Horst von Bernuth, Stephanie Thee   +4 more
doaj   +2 more sources

Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States [PDF]

Vaccines
Background/Objectives: Respiratory syncytial virus (RSV) causes a significant hospitalization burden in infants. The objective of this study was to evaluate the cost-effectiveness of introducing clesrovimab, a recently approved long-acting monoclonal ...
Klodeta Kura, John C. Lang, Dawei Wang, Yoonyoung Choi, Michelle G. Goveia, Anushua Sinha, Yao-Hsuan Chen, Elamin H. Elbasha   +7 more
doaj   +2 more sources

Cost-Effectiveness of Alternative Immunization Strategies to Protect Infants Against Respiratory Syncytial Virus in Germany: A Decision Modeling Study [PDF]

Infectious Diseases and Therapy
Introduction Germany’s Standing Committee on Vaccination (STIKO) recommends the use of monoclonal antibody nirsevimab for infants in their first respiratory syncytial virus (RSV) season; however, incorporating RSVpreF maternal vaccination may protect ...
Caroline Lade, Erin Quinn, Lea J. Bayer, Amy W. Law, Christof von Eiff, Julia Schiffner-Rohe, Mark Atwood, Bennet Huebbe, Ahuva Averin   +8 more
doaj   +2 more sources

Efficacy and safety of monoclonal antibodies against respiratory syncytial virus disease in premature infants: a systematic review and network meta-analysis [PDF]

Frontiers in Pediatrics
ObjectiveRespiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection (LRTI) in infants and young children, which may progress to bronchiolitis, pneumonia, and other severe respiratory complications.
Shunli Liu, Shunli Liu, Yan Wang, Yan Wang, Yang Cao, Yang Cao, Huiling Song, Huiling Song, Zhiqing Tian, Zhiqing Tian, Xue Li, Xue Li, Lan Huang, Lan Huang   +13 more
doaj   +2 more sources